Effectiveness study of gemcitabine, oxaliplatin, and capecitabine as first-line treatment for nonresectable biliary tract cancer

被引：0
|
作者：
Jensen, Lars Henrik
Mellergaard, Anne Haahr
Hoegdall, Dan
Larsen, Ole
机构：
[1] Vejle Hosp, Danish Colorectal Canc Grp South, Vejle, Denmark
[2] Univ Southern Denmark, Vejle, Denmark
[3] Univ Copenhagen, Herlev Hosp, Dept Oncol, DK-2730 Herlev, Denmark
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 03期
关键词：
D O I：
10.1200/jco.2014.32.3_suppl.334
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
334
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Capecitabine/oxaliplatin as first-line treatment for metastatic colorectal cancer: a meta-analysis
    Zhao, G.
    Gao, P.
    Yang, K. H.
    Tian, J. H.
    Ma, B.
    COLORECTAL DISEASE, 2010, 12 (07) : 615 - 623
  • [22] First-line treatment with oxaliplatin and capecitabine in patients with advanced or metastatic oesophageal cancer: a phase II study
    van Meerten, E.
    Eskens, F. A. L. M.
    van Gameren, E. C.
    Doorn, L.
    van der Gaast, A.
    BRITISH JOURNAL OF CANCER, 2007, 96 (09) : 1348 - 1352
  • [23] Gemcitabine, capecitabine and oxaliplatin with or without cetuximab in advanced biliary tract carcinoma
    Larsen, Finn Ole
    Hoegdall, Dan Taksony Solyom
    Hoegdall, Estrid
    Nielsen, Dorte
    ACTA ONCOLOGICA, 2016, 55 (03) : 382 - 385
  • [24] Toripalimab combined with gemcitabine and S-1 in the first-line treatment of advanced biliary tract cancer.
    Li, Wei
    Wang, Yueqi
    Yu, Yiyi
    Li, Qian
    Wang, Yan
    Zhang, Chenlu
    Xu, Xiaojing
    Guo, Xi
    Cui, Yuehong
    Hao, Qing
    Huang, Lujia
    Liu, Houbao
    Liu, Tianshu
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [25] Gemcitabine and oxaliplatin combination as first-line treatment for advanced pancreatic cancer: a multicenter phase II study
    Kyung Hee Lee
    Min Kyoung Kim
    Yeol Hong Kim
    Baek Yeol Ryoo
    Ho Yeong Lim
    Hong Suk Song
    Hoon Kyo Kim
    Myung Ah Lee
    Seock Ah Im
    Heung Moon Chang
    Jae Yong Cho
    Dae Young Zang
    Bong Seog Kim
    Jun Suk Kim
    Cancer Chemotherapy and Pharmacology, 2009, 64 : 317 - 325
  • [26] Gemcitabine and oxaliplatin combination as the first-line treatment in advanced pancreatic cancer: A multicenter phase II study
    Lee, K.
    Kim, M.
    Kim, Y.
    Ryoo, B.
    Lim, H.
    Song, H.
    Kim, H.
    Lee, M.
    Im, S.
    Chang, H.
    Cho, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [27] Gemcitabine and oxaliplatin combination as first-line treatment for advanced pancreatic cancer: a multicenter phase II study
    Lee, Kyung Hee
    Kim, Min Kyoung
    Kim, Yeol Hong
    Ryoo, Baek Yeol
    Lim, Ho Yeong
    Song, Hong Suk
    Kim, Hoon Kyo
    Lee, Myung Ah
    Im, Seock Ah
    Chang, Heung Moon
    Cho, Jae Yong
    Zang, Dae Young
    Kim, Bong Seog
    Kim, Jun Suk
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2009, 64 (02) : 317 - 325
  • [28] Gemcitabine, Docetaxel, Capecitabine, Cisplatin, Irinotecan as First-line Treatment for Metastatic Pancreatic Cancer
    Wilbur, H. Catherine
    Durham, Jennifer N.
    Lim, Su Jin
    Purtell, Katrina
    Bever, Katherine M.
    Laheru, Daniel A.
    De Jesus-Acosta, Ana
    Azad, Nilofer S.
    Wilt, Bradley
    Diaz, Luis A.
    Le, Dung T.
    Wang, Hao
    CANCER RESEARCH COMMUNICATIONS, 2023, 3 (08): : 1672 - 1677
  • [29] Capecitabine plus oxaliplatin versus gemcitabine plus oxaliplatin as first-line therapy for advanced biliary tract cancers: a multicenter, open-label, randomized, phase III, noninferiority trial
    Kim, S. T.
    Kang, J. H.
    Lee, J.
    Lee, H. W.
    Oh, S. Y.
    Jang, J. S.
    Lee, M. A.
    Sohn, B. S.
    Yoon, S. Y.
    Choi, H. J.
    Hong, J. H.
    Kim, M. -J.
    Kim, S.
    Park, Y. S.
    Park, J. O.
    Lim, H. Y.
    ANNALS OF ONCOLOGY, 2019, 30 (05) : 788 - 795
  • [30] Treatment of Patients with Advanced Biliary Tract Cancer with Either Oxaliplatin, Gemcitabine, and Capecitabine or Cisplatin and Gemcitabine-A Randomized Phase II Trial
    Markussen, Alice
    Jensen, Lars Henrik
    Diness, Laura Vittrup
    Larsen, Finn Ole
    CANCERS, 2020, 12 (07) : 1 - 10
12345